Disclosed herein are reversible and irreversible inhibitors of Bruton s tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded alone or in combination with other therapeutic agents for the treatment of autoimmune diseases or conditions heteroimmune diseases or conditions cancer including lymphoma and inflammatory diseases or conditions.